Downregulation of ST3GAL5 is associated with muscle invasion, high grade and a poor prognosis in patients with bladder cancer

Ouyang,Song; Liu,Ji‑Hong; Ni,Zhao; Ding,Guo‑Fu; Wang,Qin‑Zhang

doi:10.3892/ol.2020.11597

Downregulation of ST3GAL5 is associated with muscle invasion, high grade and a poor prognosis in patients with bladder cancer

Authors:
- Song Ouyang
- Ji‑Hong Liu
- Zhao Ni
- Guo‑Fu Ding
- Qin‑Zhang Wang
View Affiliations

Affiliations: Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Urology, First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, Xinjiang 832008, P.R. China
Published online on: May 7, 2020 https://doi.org/10.3892/ol.2020.11597
Pages: 828-840
Copyright: © Ouyang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In patients with bladder cancer (BC), the association between ST3 β-galactoside α-2,3-sialyltransferase 5 (ST3GAL5) expression and clinical outcomes, particularly regarding muscle‑invasive disease, high tumor grade and prognosis, remain unknown. In the present study, the expression of ST3GAL5 and its association with clinical outcomes in patients with BC was analyzed using various public bioinformatics databases. The difference in ST3GAL5 expression between BC and healthy bladder tissues was also evaluated using data from the Oncomine database, The Cancer Genome Atlas and Gene Expression Omnibus database. The differences in ST3GAL5 expression between muscle invasive BC (MIBC) and non‑muscle invasive BC (NMIBC), and high‑ and low‑grade BC were also analyzed. Furthermore, genes that were positively co‑expressed with ST3GAL5 in patients with BC were identified from the intersection between the Oncomine, Gene Expression Profiling Interactive Analysis 2 and UALCAN databases. Enrichment analysis by Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, Reactome pathway enrichment analyses and a gene‑concept network was performed using R package. Gene set enrichment analysis was also performed to assess the signaling pathways influenced by the high and low expression of ST3GAL5 in BC. The results indicated that ST3GAL5 expression was significantly lower in BC tissues compared with normal bladder tissues (P<0.05). Furthermore, ST3GAL5 expression in MIBC and high‑grade BC was significantly lower compared with NMIBC and low‑grade BC (P<0.05), respectively. The results from Kaplan‑Meier survival analysis result demonstrated that ST3GAL5 downregulation was associated with poor survival in patients with BC (P<0.05). Taken together, these findings suggested that ST3GAL5 may be considered as an anti‑oncogene in BC, could represent a potential predictive and prognostic biomarker for BC and may be a molecular target for tumor therapy.

View Figures

View References

1	Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387. 2018. View Article : Google Scholar : PubMed/NCBI
2	GBD 2015 Disease and Injury Incidence and Prevalence Collaborators, . Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Lond Engl. 388:1545–1602. 2016. View Article : Google Scholar
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
4	Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, Vecchia CL, Shariat S and Lotan Y: Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 63:234–241. 2012. View Article : Google Scholar : PubMed/NCBI
5	Miyazaki J and Nishiyama H: Epidemiology of urothelial carcinoma. Int J Urol. 24:730–734. 2017. View Article : Google Scholar : PubMed/NCBI
6	Witjes JA, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J, Rouanne M, et al: Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 71:462–475. 2017. View Article : Google Scholar : PubMed/NCBI
7	Berselli P, Zava S, Sottocornola E, Milani S, Berra B and Colombo I: Human GM3 synthase: A new mRNA variant encodes an NH2-terminal extended form of the protein. Biochimica Biophysica Acta. 1759:348–358. 2006. View Article : Google Scholar
8	Inokuchi JI, Inamori KI, Kabayama K, Nagafuku M, Uemura S, Go S, Suzuki A, Ohno I, Kanoh H and Shishido F: Biology of GM3 Ganglioside. Prog Mol Biol Transl. 156:151–195. 2018. View Article : Google Scholar
9	Zheng C, Terreni M, Sollogoub M and Zhang Y: Ganglioside GM3 and its role in cancer. Curr Med Chem. 26:2933–2947. 2019. View Article : Google Scholar : PubMed/NCBI
10	Hakomori SI and Handa K: GM3 and cancer. Glycoconjugate J. 32:1–8. 2015. View Article : Google Scholar
11	Satoh M, Ito A, Nojiri H, Handa K, Numahata K, Ohyama C, Saito S, Hoshi S and Hakomori SI: Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells. Int J Oncol. 19:723–731. 2001.PubMed/NCBI
12	Kawashima N, Nishimiya Y, Takahata S and Nakayama KI: Induction of Glycosphingolipid GM3 expression by valproic acid suppresses cancer cell growth. J Biol Chem. 291:21424–21433. 2016. View Article : Google Scholar : PubMed/NCBI
13	Ohyama C: Glycosylation in bladder cancer. Int J Clin Oncol. 13:308–313. 2008. View Article : Google Scholar : PubMed/NCBI
14	Edgar R, Domrachev M and Lash AE: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:207–210. 2002. View Article : Google Scholar : PubMed/NCBI
15	Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
16	Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pander A and Chinnaiyan AM: ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
17	Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al: Comprehensive analyses of tumor immunity: Implications for cancer immunotherapy. Genome Biol. 17:1742016. View Article : Google Scholar : PubMed/NCBI
18	Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017. View Article : Google Scholar : PubMed/NCBI
19	Park SJ, Yoon BH, Kim SK and Kim SY: GENT2: An updated gene expression database for normal and tumor tissues. BMC Med Genomics. 12 (Suppl 5):1012019. View Article : Google Scholar : PubMed/NCBI
20	Shin G, Kang TW, Yang S, Baek SJ, Jeong YS and Kim SY: GENT: Gene expression database of normal and tumor tissues. Cancer Informatics. 10:149–157. 2011. View Article : Google Scholar : PubMed/NCBI
21	Goldman M, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, et al: The UCSC Xena platform for public and private cancer genomics data visualization and interpretation. Biorxiv 326470. 2019.
22	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
23	Anaya J, Reon B, Chen WM, Bekiranov S and Dutta A: A pan-cancer analysis of prognostic genes. Peer J. 3:e14992016. View Article : Google Scholar : PubMed/NCBI
24	Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, et al: Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 9:32010. View Article : Google Scholar : PubMed/NCBI
25	Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH and Michor F: Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res. 18:1323–1333. 2012. View Article : Google Scholar : PubMed/NCBI
26	Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, et al: Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 20:1873–1883. 2014. View Article : Google Scholar : PubMed/NCBI
27	Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ and Chu IS: Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol. 28:2660–2667. 2010. View Article : Google Scholar : PubMed/NCBI
28	Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Pejavar S, et al: Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 11:4044–4055. 2005. View Article : Google Scholar : PubMed/NCBI
29	Sanchez-Carbayo M, Socci ND, Lozano J, Saint F and Cordon-Cardo C: Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 24:778–789. 2006. View Article : Google Scholar : PubMed/NCBI
30	Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SG, Segraves R, de Rycke Y, Elvin P, Cassidy A, Spraggon C, et al: Regional copy number-independent deregulation of transcription in cancer. Nat Genet. 38:1386–1396. 2006. View Article : Google Scholar : PubMed/NCBI
31	Yu G, Wang LG, Han Y and He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
32	Yu G and He QY: ReactomePA: An R/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst. 12:477–479. 2016. View Article : Google Scholar : PubMed/NCBI
33	Sjödahl G, Eriksson P, Liedberg F and Höglund M: Molecular classification of urothelial carcinoma: Global mRNA classification versus tumour-cell phenotype classification. J Pathology. 242:113–125. 2017. View Article : Google Scholar
34	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc National Acad Sci. 102:15545–15550. 2005. View Article : Google Scholar
35	Villanueva RAM and Chen ZJ: ggplot2: Elegant graphics for data analysis. (2nd). Meas Interdiscip Res Perspectives. 17:160–167. 2019. View Article : Google Scholar
36	Nykopp TK, Batista da Costa J, Mannas M and Black PC: Current clinical trials in non-muscle invasive bladder cancer. Curr Urol Rep. 19:1012018. View Article : Google Scholar : PubMed/NCBI
37	Kaufman DS, Shipley WU and Feldman AS: Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
38	Heijden AGvd and Witjes JA: Recurrence, progression, and follow-up in non-muscle-invasive bladder cancer. Eur Urol Suppl. 8:556–562. 2009. View Article : Google Scholar
39	Wang H, Isaji T, Satoh M, Li D, Arai Y and Gu J: Antitumor effects of exogenous ganglioside GM3 on bladder cancer in an orthotopic cancer model. Urology. 81:210.e211–215. 2012.
40	Li Q, Sun M, Yu M, Fu Q, Jiang H, Yu G and Li G: Gangliosides profiling in serum of breast cancer patient: GM3 as a potential diagnostic biomarker. Glycoconjugate J. 36:419–428. 2019. View Article : Google Scholar
41	Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, Vázquez AM and Fainboim L: Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in High-Risk and metastatic breast cancer patients. J Immunother. 29:215–223. 2006. View Article : Google Scholar : PubMed/NCBI
42	Cai H, Zhou H, Miao Y, Li N, Zhao L and Jia L: MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5. Lab Invest. 97:530–542. 2017. View Article : Google Scholar : PubMed/NCBI
43	Kawamura S, Ohyama C, Watanabe R, Satoh M, Saito S, Hoshi S, Gasa S and Orikasa S: Glycolipid composition in bladder tumor: A crucial role of GM3 ganglioside in tumor invasion. Int J Cancer. 94:343–347. 2001. View Article : Google Scholar : PubMed/NCBI
44	Chung TW, Choi HJ, Kim SJ, Kwak CH, Song KH, Jin UH, Chang YC, Chang HW, Lee YC, Ha KT and Kim CH: The ganglioside GM3 is associated with cisplatin-induced apoptosis in human colon cancer cells. PLoS One. 9:e927862014. View Article : Google Scholar : PubMed/NCBI
45	Massagué J: TGFβ in Cancer. Cell. 134:215–230. 2008. View Article : Google Scholar : PubMed/NCBI
46	Colak S and Ten Dijke P: Targeting TGF-β signaling in cancer. Trends Cancer. 3:56–71. 2017. View Article : Google Scholar : PubMed/NCBI
47	Newman AC and Maddocks ODK: One-carbon metabolism in cancer. Brit J Cancer. 116:1499–1504. 2017. View Article : Google Scholar : PubMed/NCBI
48	Moore LE, Malats N, Rothman N, Real FX, Kogevinas M, Karami S, García-Closas R, Silverman D, Chanock S, Welch R, et al: Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer. Int J Cancer. 120:2452–2458. 2007. View Article : Google Scholar : PubMed/NCBI
49	Li X, Che K, Wang L, Zhang T, Wang G, Pang Z, Shen H and Du J: Subcellular localization of β-arrestin1 and its prognostic value in lung adenocarcinoma. Medicine. 96:e84502017. View Article : Google Scholar : PubMed/NCBI
50	Liu J, Wang H, Huang C and Qian H: Subcellular localization of MTA proteins in normal and cancer cells. Cancer Metastasis Rev. 33:843–856. 2014. View Article : Google Scholar : PubMed/NCBI
51	Kim HJ, Lee SY, Kim CY, Kim YH, Ju W and Kim SC: Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells. Oncotarget. 8:6608–6622. 2017. View Article : Google Scholar : PubMed/NCBI
52	Boudhraa Z, Bouchon B, Viallard C, D'Incan M and Degoul F: Annexin A1 localization and its relevance to cancer. Clin Sci (Lond). 130:205–220. 2016. View Article : Google Scholar : PubMed/NCBI
53	Mollinedo F: Neutrophil degranulation, plasticity, and cancer metastasis. Trends Immunol. 40:228–242. 2019. View Article : Google Scholar : PubMed/NCBI
54	Hanahan D and Weinberg Robert A: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
55	Takeuchi H, Tanaka M, Tanaka A, Tsunemi A and Yamamoto H: Predominance of M2-polarized macrophages in bladder cancer affects angiogenesis, tumor grade and invasiveness. Oncol Lett. 11:3403–3408. 2016. View Article : Google Scholar : PubMed/NCBI
56	Coffelt SB, Wellenstein MD and de Visser KE: Neutrophils in cancer: Neutral no more. Nat Rev Cancer. 16:431–446. 2016. View Article : Google Scholar : PubMed/NCBI
57	Kent A and Blander JM: Nod-like receptors: Key molecular switches in the conundrum of cancer. Front Immunol. 5:1852014. View Article : Google Scholar : PubMed/NCBI
58	Saxena M and Yeretssian G: NOD-like receptors: Master regulators of inflammation and cancer. Front Immunol. 5:3272014. View Article : Google Scholar : PubMed/NCBI
59	Ozaki K and Leonard WJ: Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem. 277:29355–29358. 2002. View Article : Google Scholar : PubMed/NCBI
60	Pencik J, Pham HTT, Schmoellerl J, Javaheri T, Schlederer M, Culig Z, Merkel O, Moriggl R, Grebien F and Kenner L: JAK-STAT signaling in cancer: From cytokines to non-coding genome. Cytokine. 87:26–36. 2016. View Article : Google Scholar : PubMed/NCBI
61	Trivedi S and Starz-Gaiano M: Drosophila Jak/STAT signaling: Regulation and relevance in human cancer and metastasis. Int J Mol Sci. 19:40562018. View Article : Google Scholar